1. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

   • Masahiro Tsuboi
   • Roy S. Herbst
   • Yi-Long Wu

   Summary of Research Open access 11 March 2024 Pages: 131 - 134

   

2. Inotuzumab in Older Patients with Newly Diagnosed Acute Lymphoblastic Leukemia—A Podcast

   • Elias J. Jabbour
   • Matthias Stelljes

   Commentary Open access 08 March 2024 Pages: 135 - 141

3. Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review

   • Urszula Żebrowska
   • Walentyna Balwierz
   • Aleksandra Wieczorek

   Systematic Review Open access 24 February 2024 Pages: 143 - 159

   

4. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review

   • Patrick Crotty
   • Karim Kari
   • Matt Vassar

   Systematic Review 11 March 2024 Pages: 161 - 173

   

5. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

   • Tomas Buchler
   • Alexandr Poprach

   Review Article Open access 03 February 2024 Pages: 175 - 180

6. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G

   • Toshihiko Matsumoto
   • Yoshiyuki Yamamoto
   • Kei Muro

   Original Research Article Open access 01 March 2024 Pages: 181 - 190

   

7. Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK

   • Rachael Batteson
   • Emma Hook
   • Paul K. Paik

   Original Research Article Open access 16 March 2024 Pages: 191 - 201

   

8. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies

   • Bi-Cheng Wang
   • Bo-Hua Kuang
   • Guo-He Lin

   Original Research Article 30 January 2024 Pages: 203 - 212

   

9. Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

   • Alexander Olkus
   • Aurelie Tomczak
   • Michael T. Dill

   Original Research Article Open access 28 February 2024 Pages: 213 - 221

   

10. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

    • Margherita Rimini
    • Eleonora Loi
    • Andrea Casadei-Gardini

    Original Research Article 12 February 2024 Pages: 223 - 235

    

11. Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia

    • Dian Jin
    • Haoguang Chen
    • Zhen Cai

    Original Research Article Open access 11 March 2024 Pages: 237 - 249

    

12. Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study

    • Gwan Hee Han
    • Hae-Rim Kim
    • Hanbyoul Cho

    Original Research Article 28 February 2024 Pages: 251 - 262

    

13. DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

    • Julia Maria Ressler
    • Erwin Tomasich
    • Anna Sophie Berghoff

    Original Research Article Open access 24 February 2024 Pages: 263 - 275

    

14. EGFR and ERBB2 Exon 20 Insertion Mutations in Chinese Non-small Cell Lung Cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation

    • Ruiying Zhao
    • Jiaqi Li
    • Yuchen Han

    Original Research Article 28 February 2024 Pages: 277 - 288

    

15. Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer

    • Connie Kang

    Adis Drug Evaluation 06 March 2024 Pages: 289 - 296